You are here

Akut Antikor Aracılı Renal Allograt Rejeksiyonunda Çift Filtrasyon Plazmaferez: Üç Vaka Bildirimi

Utility of Double Filtration Plasmapheresis in Acute Antibody Mediated Renal Allograft Rejection: Report of Three Cases

Journal Name:

Publication Year:

DOI: 
10.5262/tndt.2011.1003.17

Keywords (Original Language):

Abstract (2. Language): 
Plasmapheresis is an extracorporeal procedure, which is often employed to rapidly lower circulating titers of autoantibodies, immune complexes or toxins. There are two types of plasmapheresis namely, regular plasmapheresis (RPP) by centrifugation and membrane fi ltration, and double fi ltration plasmapheresis (DFPP) which is a special form of membrane fi ltration in which two membranes called as plasma separator and plasma fractionator are employed to fi lter macromolecules more selectively. DFPP have several advantages over RP. Despite widespread utilization of DFPP in the setting of ABO blood group incompatible kidney transplantation, there is no report regarding DFPP in patients with antibody mediated acute renal allograft rejection who are good candidates for benefi cial effects of DFPP. Here we report three renal transplant recipients in whom DFPP was applied as a component of anti-rejection treatment regimen.
Abstract (Original Language): 
Plazmaferez, dolaşımdaki antikor, immün kompleks ve toksin düzeylerini hızla düşürmek için kullanılan bir ekstrakorporeal yöntemdir.İki tip plazmaferez bulunmaktadır: Santrifüj ve membran fi ltrasyonu ile yapılan regüler plazmaferez (RP) ve büyük moleküllerin daha selektif olarak fi ltre edildiği, plazma ayırıcısı ve plazma fraksiyoneri olarak adlandırılan iki membranın kullanıldığı özel bir fi ltrasyon şekli olan çift fi ltrasyon plazmaferezdir (ÇFP).ÇFP’nin RP’ye göre bazı avantajları vardır. ABO uyumsuzluğunda böbrek nakli uygulamasında ÇFP yaygın olarak kullanılmasına rağmen, ÇFP’nin faydalı etkileri için iyi bir aday olabilecek antikor aracılı akut renal allograft rejeksiyonu olan hastalarda ÇFP ile ilgili vaka bildirimi yoktur. Burada rejeksiyon tedavisinin bir parçası olarak ÇFP uygulanan üç renal transplant hastasını bildirmekteyiz.
301-303

REFERENCES

References: 

1. Madore F: Plasmapheresis. Technical aspects and indications. Crit
Care Clin 2002; 18: 375-392
2. Singh N, Pirsch J, Samaniego M: Antibody-mediated rejection:
Treatment alternatives and outcomes. Transplant Rev (Orlando)
2009; 23: 34-46
3. Colvin RB: Antibody-mediated renal allograft rejection: Diagnosis
and pathogenesis. J Am Soc Nephrol 2007; 18: 1046-1056
4. Colvin RB, Nickeleit V: Renal transplant pathology. In Jennette JC,
Olson JL, Schwartz MM, Silva FG (eds). Pathology of the Kidney
(6th ed). Philadelphia: Lippincott-Raven, 2006; 1347-1490
5. Shimmura H, Tanabe K, Ishikawa N, Tokumoto T, Fuchinoue S,
Takahashi K, Toma H, Agishi T: Removal of anti-A/B antibodies
with plasmapheresis in ABO-incompatible kidney transplantation.
Ther Apher Dial 2000; 4: 395-398
6. Tanabe K: Double-fi ltration plasmapheresis. Transplantation 2007;
84(12): 30-32
7. Ramunni A, Lauletta G, Brescia P, Saliani MT, Montrone M,
Chironna M, Sansonno D, Dammacco F, Coratelli P: Doublefi
ltration plasmapheresis in the treatment of leg ulcers in
cryoglobulinemia. J Clin Apher 2008; 23: 118-122
8. Hajime N, Michiko A, Atsunori K,Tatsuo K, Yuko N, Naoki
O, Katsuhiko S: A case report of effi ciency of double fi ltration
plasmapheresis in treatment of Goodpasture’s syndrome. Ther
Apher Dial 2009; 13: 373-377
9. Ramunni A, De Robertis F, Brescia P, Saliani MT, Amosuro M,
Prontera M, Dimonte E, Trojano M, Coratelli P: A case report of
double fi ltration plasmapheresis in an acute episode of multiple
sclerosis. Ther Apher Dial 2008; 12: 250-254
10. Agishi T, Kaneko I, Hasuo Y Hayasaka Y, Sanaka T, Ota K,
Amemiya H, Sugino N, Abe M, Ono T, Kawai S, Yamane T: Double
fi ltration plasmapheresis. 1980. Ther Apher Dial 2000; 4: 29-33
11. Mineshima M, Akiba T: Double fi ltration plasmapheresis in critical
care. Ther Apher 2002; 6: 180-183
12. Siami GA, Siami FS: Membrane plasmapheresis in the United States:
A review over the last 20 years. Ther Apher 2001; 5: 315-320

Thank you for copying data from http://www.arastirmax.com